EarningsBeats.com Digest for April 8, 2020
|
Trading Places Live!
Join Tom Bowley for a briefing on market activity on Mondays and Wednesdays from 9-9:30 am EST before the opening bell. Click here to listen live! The recording will be posted to our YouTube channel - be sure to subscribe to receive a notification!
Dear EarningsBeats Digest Member,
Friday, April 10 - Inside the EarningsBeats WAR Room
Join Tom Bowley, Chief Market Strategist, as he details the changes that he's made to his short-term trading strategy. With a Volatility Index ($VIX) still at a very elevated level and stock market and economic paradigm shifts underway, opportunities of a lifetime are being created. These opportunities, however, will not fall into our laps. We need to do the research and hard work to uncover these gems early. That's the purpose of this initial WAR Room
gathering of our EarningsBeats.com community. Tom will describe many of his techniques and share with you the ChartLists he's creating to organize his trading approach. This will include identifiying specific long/short trading candidates. This will be a highly educational event that will maximize
your opportunity for trading success during one of the most challenging periods of our lifetime.
This is an EarningsBeats members-only event. To sign up for a NO COST 30-day trial and receive access to this event, click below. We hope to see you there!
One Biotech That Will Likely Benefit From This Pandemic
When the stock market finally recovered from the financial system meltdown in 2008/2009, what was the first order of business? To make sure we never pushed our financial system to its limit ever again. When a crisis unfolds, not only do we figure out how to handle that crisis, but we completely overreact to ensure it doesn't happen again. We'll see this same strategy unfold once we've all moved past COVID-19. We'll be ready for the next
pandemic, even if one doesn't occur for the next 100 years. One biotech company, Regeneron Pharmaceuticals (REGN), specializes in infectious diseases. The company currently has a partnership with the Department of Health & Human Services as it attempts to discover a vaccine to protect everyone from this virus. Investors recognize the significance of REGN's efforts. Simply check out the heavy volume, relative strength and accumulation/distribution:
In addition to REGN garnering a lot of attention because of COVID-19, the biotech group ($DJUSBT) as a whole has traded sideways for most of the last 5 years. But that seems to be changing as the DJUSBT has been trending much higher vs. the S&P 500. I believe this is an industry group that's likely to outperform for years to come. Another breakout above the February high could really light a fire under this group. If it happens,
expect REGN to be a significant beneficiary.
Happy trading!
Tom Bowley
Chief Market Strategist
EarningsBeats.com
Better Timing. Better Trades.
|
|
|
